水飞蓟宾胶囊结合非诺贝特片治疗非酒精性脂肪肝的疗效评价

Efficacy evaluation of silybin capsule combined with fenofibrate in the treatment of nonalcoholic fatty liver

目的探究水飞蓟宾胶囊结合非诺贝特片治疗非酒精性脂肪肝的临床疗效。方法选取2017年3月至2019年5月在我院治疗的非酒精性脂肪肝患者118例为研究对象,随机分为观察组和对照组,每组各59例。观察组59例采用水飞蓟宾胶囊结合非诺贝特片治疗,对照组59例采用水飞蓟宾胶囊治疗。治疗结束后以观察组与对照组患者的临床疗效、肝功能、血糖、血尿酸、血脂、炎症指标、肝脾CT比值、安全性指标为评价指标。结果观察组患者的临床有效率96.61%显著高于对照组的77.97%,差异具统计学意义(P<0.05)。观察组与对照组患者血清GPT、GOT、GGT水平均比治疗前显著降低,且观察组明显低于对照组,差异显著(P<0.05);治疗后观察组与对照组患者的FBG、FINS及SUA水平比治疗前差异明显,且观察组明显低于对照组,具显著差异(P<0.05);观察组与对照组患者血清TC、TG、LDL-C均发生显著下降,且观察组降幅比对照组明显大,HDL-C均显著升高,且观察组比对照组升高幅度更显著;观察组与对照组患者的血清IL-6、TNF-α及NF-κB与对照组相比,均明显降低,且观察组降低幅度大于对照组,差异明显(P<0.05);观察组与对照组肝脾CT比值均比治疗前显著增高,且观察组升高幅度大于对照组,差异显著(P<0.05);观察组与对照组患者不良反应无显著差异(P>0.05)。结论水飞蓟宾胶囊结合非诺贝特片治疗非酒精性脂肪肝可显著提高临床疗效,增强肝功能,改善血糖、血脂及血尿酸水平,降低炎症指标水平,安全性好,值得临床推广。

Objective To explore the clinical efficacy of silybin capsules combined with fenofibrate tablets in the treatment of non-alcoholic fatty liver.Methods One hundred and eighteen patients with non-alcoholic fatty liver treated in our hospital from March 2017 to May 2019 were selected as the research subjects and randomly divided into observation group and control group,with 59 cases in each group.Fifty-nine patients in the observation group were treated with silybin capsules and fenofibrate tablets,and 59 patients in the control group were treated with silybin capsules.After treatment,the clinical efficacy,liver function,blood glucose and blood uric acid,blood lipid,inflammation index,liver and spleen CT ratio,and safety index were used as the evaluation indicators.Results The clinical effective rate of the observation group was 96.61%,which was significantly higher than that of the control group(77.97%).The difference was statistically significant(P<0.05).The serum levels of ALT,AST and GGT in the observation group and the control group were significantly lower than those in the control group,and the observation group was significantly lower than the control group,the difference was significant(P<0.05).After treatment,the FBG,FINS and the control group were compared with the control group.The level of SUA was significantly different from that before treatment,and the observation group was significantly lower than the control group,with significant difference(P<0.05).The serum levels of TC,TG and LDL-C in the observation group and the control group were significantly decreased,and the observation group decreased greater than that of the control group.HDL-C was significantly increased,and the observation group was more significant than the control group.The serum IL-6,TNF-αand NF-κB in the observation group were compared with the control group.The decrease was significantly lower in the observation group than in the control group,and the difference was significant(P<0.05).The CT ratio of the liver and spleen in the observation group and the control group was significantly higher than that before the treatment,and the increase in the observation group was greater than that in the control group,and the difference was significant(P<0.05).There was no significant difference in adverse reactions between the observation group and the control group(P>0.05).Conclusion Silybin capsules combined with fenofibrate tablets in the treatment of non-alcoholic fatty liver can significantly improve clinical efficacy,enhance liver function,improve blood glucose,blood lipid and blood uric acid levels,reduce inflammation levels,and have good safety.It is worthy of clinical promotion.